Male hypogonadism arises from a deficiency in testosterone secretion that may occur naturally with increasing age, or as a result of malfunction of the hypothalamus, pituitary gland or testes. Tostran® (also known as Fortigel®, Itnogen® and Tostrex®) is a metered-dose gel formulation of 2% testosterone that was recently developed to treat male hypogonadism and to overcome the disadvantages exhibited by some testosterone formulations.
Methods:
A prospective Phase II trial of Tostran in men with primary or secondary hypogonadism evaluating the effect of showering was conducted.
Results:
This trial demonstrated that showering 2 h after application of Tostran has no significant effect on serum testosterone levels.
Conclusion:
Market research in the UK and Germany has indicated that endocrinologists would consider switching patients to Tostran from other formulations, especially other gels. Their preference is due to the dosage and administration advantages of Tostran, the flexibility of the metered-dose formulation, and the ability to shower 2 h after application.
Get full access to this article
View all access options for this article.
References
1.
RommertsF.F.G.Testosterone: an overview of biosynthesis, transport, metabolism and nongenomic actions. In: NieschlagE., BehreH.M. editors. Testosterone. Action, Deficiency, Substitution. Heidelberg: Springer-Verlag; 1998.
NieschlagE., SwerdloffR., BehreH.M., GoorenL.J., KaufmanJ.M., LegrosJ.J., et al.Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol, 2005; 48:1–4.
4.
OrwollE., LambertL.C., MarshallL.M., BlankJ., Barrett-ConnorE., CauleyJ., et al.Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med, 2006; 166:2124–2131.
5.
ShoresM.M., MatsumotoA.M., SloanK.L., KivlahanD.R.Low serum testosterone and mortality in male veterans. Arch Intern Med, 2006; 166:1660–1665.
6.
ZitzmannM., NieschlagE.Testosterone levels in healthy men and the relation to behavioural and physical characteristics: facts and constructs. Eur J Endocrinol, 2001; 144:183–197.
7.
AraujoA.B., O’DonnellA.B., BrambillaD.J., SimpsonW.B., LongcopeC., MatsumotoA.M., et al.Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab, 2004; 89:5920–5926.
8.
GouldD.C., AmorosoP., KirbyR.S.Hypoandrogen–metabolic syndrome: a significant issue for men's health. BJU Int, 2006; 98:494–496.
9.
MulliganT., FrickM.F., ZurawQ.C., StemhagenA., McWhirterC.Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract, 2006; 60:762–769.
10.
BagatellC.J., BremnerW.J.Androgens in men – uses and abuses. N Engl J Med, 1996; 334:707–714.
11.
MatsumotoA.M.Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am, 1994; 23:857–875.
12.
MeinhardtW., KropmanR.F., VermeijP.Comparative tolerability and efficacy of treatments for impotence. Drug Saf, 1999; 20:133–146.
13.
LundB.C., Bever-StilleK.A., PerryP.J.Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy, 1999; 19:951–956.
14.
VermeulenA.Androgen replacement therapy in the aging male – a critical evaluation. J Clin Endocrinol Metab, 2001; 86:2380–2390.
15.
HandelsmanD.J., ZajacJ.D.Androgen deficiency and replacement therapy in men. MJA Practice Essentials, 2004; 180:529–535.
16.
SnyderP.J., LawrenceD.A.Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab, 1980; 51:1335–1339.
17.
FindlayJ.C., PlaceV., SnyderP.J.Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab, 1989; 68:369–373.
18.
JordanW.P.Jr., AtkinsonL.E., LaiC.Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin Ther, 1998; 20:80–87.
19.
NieschlagE., BehreH.M., BouchardP., CorralesJ.J., JonesT.H., StallaG.K., et al.Testosterone replacement therapy: current trends and future directions. Hum Reprod Update, 2004; 10:409–419.
20.
SwerdloffR.S., WangC., CunninghamG., DobsA., IranmaneshA., MatsumotoA.M., et al.Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab, 2000; 85:4500–4510.
Food and Drug Administration. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Good Clinical Practice: Consolidated Guidance (ICH-E6). Rockville, MD: Centre for Drug Evaluation and Research, FDA; 1997.
26.
World Medical Association, Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire: WMA; 2006. Available at: http://www.wma.net/e/policy/pdf/17c.pdf..
